N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2889-2894

  De Lima Junior, Mario MacIel ^a   Reis, Leonardo Oliveira ^a   Guilhen, Ana Carolina Trindade ^a   Granja, Fabiana ^a   De Lima Oliveira, Mariana Nicolau ^a   Ferreira, Ubirajara ^a   Cunha, Lucas Leite ^a   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Acetylation; Benign prostatic hyperplasia; NAT2 genotype; Prostate cancer; Risk

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ADULT; AGED; ARTICLE; BLOOD DONOR; CANCER PATIENT; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LATIN AMERICA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84867993255     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0157-4     Document Type: Article

References (27)

1. INCA Instituto Nacional do Cancer (INCA): Available in: http://www.inca.gov.br/.
2. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859.
3. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer. 1997;80:1261.
4. Reis LO, Sasse AD, Matheus WE, Denardi F, Stopiglia RM, da Silva MM, Ferreira U. Prostate cancer: evidence based clinical practice. Actas Urol Esp. 2009;33:344.
5. Reis LO, Zani EL, Alonso JC, Simões FA, Rejowski RF, Ferreira U. Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study. Actas Urol Esp. 2011;35:10.
6. Reis LO, Vieira LF, Zani EL, Denardi F, de Oliveira LC, Ferreira U. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer. J Investig Med. 2010;58:957.
7. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14:473.
8. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, et al. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun. 1992;185:839.
9. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis. 1995;16:39.
10. Patrianakos C, Hoffmann D. Chemical studies on tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. J Anal Toxcol. 1979;3:150.
11. Rodriguez C, Tatham LM, Thun MJ, Calle EE, Heath CW Jr. Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol. 1997;145:466.
12. Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8:25.
13. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res. 1997;57:195.
14. Wang CY, Debiec-Rychter M, Schut HA, Morse P, Jones RF, Archer C, et al. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis. 1999;20:1591.
15. Lawson T, Kolar C. Human prostate epithelial cells metabolize chemicals of dietary origin to mutagens. Cancer Lett. 2002;175:141.
16. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst. 1994;86:252.
17. Guilhen ACT, Bufalo NE, Morari EC, Leite JL, Assumpção LVM, Tincani AJ, Ward LS. Role of the N-acetyltransferase-2 detoxification system in thyroid cancer susceptibility. Clin Cancer Res. 2009;15:406.
18. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics. 1999;9:333.
19. Hamasaki T, Itamoni H, Katoh T, Aono H, Ikuyama T, Marutami T, et al. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol. 2003;10:167.
20. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C, Medeiros R. Acetylation genotype and the genetic susceptibility to prostate cancer in a Southern European population. Prostate. 2005;64:246.
21. Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol. 2005;5:12.
22. Rovito PM Jr, Morse PD, Spinek K, Newman N, Jones RF, Wang CY, et al. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:69.
23. Iguchi T, Sugita S, Wang CY, Newman NB, Nakatani T, Haas GP. MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo. 2009;23:7.
24. Sharma S, Cao X, Wilkens LR, Yamamoto J, Lum-Jones A, Henderson BE, Kolonel LN, Le Marchand L. Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19:1866.
25. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis. 2008;11:349.
26. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146.
27. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002;506-507:65.